BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tovok: Preliminary Phase II data

Preliminary data from 74 evaluable patients in an ongoing, open-label Phase II trial showed that 22% of patients treated with 50 mg daily Tovok (n=34) achieved a partial response vs. 13% of patients treated with Erbitux cetuximab (n=40). Diarrhea and skin-related disorders were the most...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >